List view / Grid view
11 July 2016 | By Victoria White, Digital Content Producer
This license agreement opens new markets to Celyad and expands the global footprint of its NKR-2 T-cell cancer immunotherapy treatment...
28 June 2016 | By Victoria White, Digital Content Producer
Celyad has announced headline results for CHART-1, its European Phase III clinical trial for its lead cardiovascular disease product candidate - C-Cure...
23 June 2016 | By Victoria White, Digital Content Producer
The study is evaluating Celyad's NKR-2 T-cell therapy using T-cells with NKG2D receptor in patients suffering from AML or multiple myeloma...
26 May 2016 | By Victoria White, Digital Content Producer
Celyad has completed the safety follow-up of the third dose level cohort in its Phase I/IIa clinical trial of its NKR-2 T-cell therapy...
30 March 2016 | By Victoria White
Celyad has announced the completion of the safety follow-up of the first patient in the third dose level in the Phase I/IIa of its NKR-2 T-cell therapy...
25 February 2016 | By Victoria White
The Phase I trial is designed to assess the safety and feasibility of NKR-2, in two different haematological indications...
Natural killer receptor T-cells have the potential to become a real game changing treatment for patients with cancer. Here, Dr Frédéric Lehmann, VP Immuno-Oncology, Celyad, discusses this new cancer fighting technology...
3 February 2016 | By Victoria White
Celyad has appointed Dr Richard Mountfield as Vice-President of Global Regulatory Affairs...
5 January 2016 | By Victoria White
CAR-NKG2D is a chimeric antigen receptor (CAR) T-Cell autologous therapy that has the potential to target ligands present on a broad range of solid tumours and blood cancers...
21 December 2015 | By Victoria White
The FDA has authorised Celyad’s IND application to proceed, thus allowing for the clinical testing of C-Cure cardiopioetic cells delivered via C-Cathez in a Phase III heart failure trial...
2 December 2015 | By Victoria White
Celyad has announced the infusion of the first patient of the second cohort of its Phase I clinical trial evaluating it's NKG2D CAR T-Cell therapy in acute myeloid leukaemia and multiple myeloma...
7 September 2015 | By Victoria White
Dr Roychowdury brings over 15 years of comprehensive pharmaceutical industry experience and 14 years of patient care and academic research to the role with Celyad...
3 August 2015 | By Victoria White
Celyad has completed the injection procedure for the last patient enrolled in CHART-1, its Phase III clinical trial of cardiovascular candidate, C-Cure...
11 June 2015 | By Victoria White
Celyad has completed the 30-day safety follow-up of the first patient enrolled in a Phase I clinical trial evaluating the safety of NKG2D CAR T-cell therapy..
6 May 2015 | By Victoria White
All resolutions presented at Cardio3 BioSciences' Annual Shareholder Assembly were duly passed including a name change for the Company to Celyad...
